BAP1 and neoplasm: Similarly, Li et al. [77] conducted a comprehensive analysis using scRNA-seq on 37,660 malignant cells from 17 UM tumor samples, uncovering distinct intra-tumoral subtypes with varying prognoses and immune microenvironments, and identified a 9-gene signature (including BAP1, SF3B1, etc.)that stratifies patients based on tumor cell heterogeneity, providing a valuable tool for personalized treatment strategies.